Vascular Endothelial Growth Factor A
"Vascular Endothelial Growth Factor A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The original member of the family of endothelial cell growth factors referred to as VASCULAR ENDOTHELIAL GROWTH FACTORS. Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as "tumor angiogenesis factor" and "vascular permeability factor". Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating VASODILATION via NITRIC OXIDE-dependent pathways. Alternative splicing of the mRNA for vascular endothelial growth factor A results in several isoforms of the protein being produced.
| Descriptor ID |
D042461
|
| MeSH Number(s) |
D12.644.276.100.800.200 D12.776.467.100.800.200 D23.529.100.800.200
|
| Concept/Terms |
Vascular Endothelial Growth Factor A- Vascular Endothelial Growth Factor A
- Vascular Endothelial Growth Factor-A
- VEGF-A
- Vasculotropin
- VEGF
- Vascular Endothelial Growth Factor
- Vascular Permeability Factor
- Permeability Factor, Vascular
|
Below are MeSH descriptors whose meaning is more general than "Vascular Endothelial Growth Factor A".
Below are MeSH descriptors whose meaning is more specific than "Vascular Endothelial Growth Factor A".
This graph shows the total number of publications written about "Vascular Endothelial Growth Factor A" by people in this website by year, and whether "Vascular Endothelial Growth Factor A" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 2 | 2 |
| 1995 | 0 | 4 | 4 |
| 1996 | 0 | 3 | 3 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 5 | 5 |
| 2000 | 0 | 5 | 5 |
| 2001 | 0 | 7 | 7 |
| 2002 | 0 | 9 | 9 |
| 2003 | 4 | 6 | 10 |
| 2004 | 4 | 10 | 14 |
| 2005 | 5 | 9 | 14 |
| 2006 | 2 | 8 | 10 |
| 2007 | 5 | 11 | 16 |
| 2008 | 8 | 13 | 21 |
| 2009 | 10 | 7 | 17 |
| 2010 | 3 | 14 | 17 |
| 2011 | 9 | 5 | 14 |
| 2012 | 3 | 11 | 14 |
| 2013 | 7 | 14 | 21 |
| 2014 | 3 | 9 | 12 |
| 2015 | 2 | 8 | 10 |
| 2016 | 4 | 6 | 10 |
| 2017 | 1 | 4 | 5 |
| 2018 | 3 | 5 | 8 |
| 2019 | 3 | 5 | 8 |
| 2020 | 3 | 5 | 8 |
| 2021 | 2 | 5 | 7 |
| 2022 | 2 | 4 | 6 |
| 2023 | 0 | 5 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vascular Endothelial Growth Factor A" by people in Profiles.
-
Bioflavonoid luteolin prevents sFlt-1 release via HIF-1a inhibition in cultured human placenta. FASEB J. 2023 08; 37(8):e23078.
-
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023 Jul 01; 402(10395):41-53.
-
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer. Ann Oncol. 2023 08; 34(8):714-722.
-
Multi-omic characterization of brain changes in the vascular endothelial growth factor family during aging and Alzheimer's disease. Neurobiol Aging. 2023 06; 126:25-33.
-
Histotripsy induces apoptosis and reduces hypoxia in a neuroblastoma xenograft model. Int J Hyperthermia. 2023; 40(1):2222941.
-
Long-Term Maternal Metabolic and Cardiovascular Phenotypes after a Pregnancy Complicated by Mild Gestational Diabetes Mellitus or Obesity. Am J Perinatol. 2023 04; 40(6):589-597.
-
Association of fetal sex with angiogenic factors in normotensive and hypertensive pregnancy states. Pregnancy Hypertens. 2022 Aug; 29:108-115.
-
Robust coupling of angiogenesis and osteogenesis by VEGF-decorated matrices for bone regeneration. Acta Biomater. 2022 09 01; 149:111-125.
-
Amniotic growth factors enhanced human pre-adipocyte cell viability and differentiation under hypoxia. J Biomed Mater Res B Appl Biomater. 2022 09; 110(9):2146-2156.
-
Fluctuations in central foveal thickness and association with vision outcomes with anti-VEGF therapy for nAMD: HARBOR post hoc analysis. BMJ Open Ophthalmol. 2022; 7(1):e000957.